



H1 2022 RESULTS

August 3, 2022

Disclaimer



In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. (“DiaSorin” or the “Company” and, together with its subsidiary the “Group”). The Presentation is being furnished to you for information purposes only and for use in presentations of the industrial plan of the Group.

No distribution of this Presentation. This Presentation is being furnished to you solely for your information and may not be reproduced, in whole or in part, or redistributed to any other individual or legal entity.

Verbal explanation. This Presentation has to be accompanied by a verbal explanation. A simple reading of this Presentation without the appropriate verbal explanation could give rise to a partial or incorrect understanding.

No offer to purchase or sell securities. The information, statements and opinions contained in this Presentation are for information purposes only and do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to purchase or subscribe for securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

Rounding. Due to rounding, numbers presented throughout this Presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Miscellanea. This Presentation has been prepared on a voluntary basis. DiaSorin is therefore not bound to prepare similar presentations in the future, unless where provided by law. Neither the Company nor any member of the Group nor any of its or their respective representatives, directors, employees or agents accept any liability whatsoever in connection with this Presentation or any of its contents or in relation to any loss arising from its use or from any reliance placed upon it.

Piergiorgio Pedron, the manager responsible for the preparation of the company accounting documents for DiaSorin S.p.A., declares that, pursuant to Article 154-bis, paragraph 2, of the Legislative Decree February 24, 1998, no. 58, to the best of his knowledge, the accounting information included in this Presentation correspond to document results, books and accounting records.

Forward-looking statements

This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaSorin may make forward-looking statements orally to analysts, investors, representatives of the media and others. In particular, among other statements, certain statements regarding future financial performance, the achievement of certain targeted metrics at any future date or for any future period, trends in results of operations, margins, costs, return on capital, risk management and competition are forward-looking in nature. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance and are, by their nature, subject to inherent risks, uncertainties and assumptions that are difficult to predict because they relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Forward-looking statements do not take into account any additional effects that may arise from impacts on the global market in which DiaSorin operates and, more generally, on the macroeconomic scenario, also following any eventual governmental measures related to the spread of COVID-19 and any potential delay in the vaccination campaign.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the impact of the COVID-19 pandemic, the ability of the Group to create and launch new products successfully; changes in the global financial markets, general economic environment and changes in demand for diagnostic/healthcare/life sciences products, which is subject to cyclicity; changes in local economic and political conditions, changes in trade policy and the imposition of global and regional tariffs or tariffs targeted to the diagnostic/healthcare/life sciences industry, the enactment of tax reforms or other changes in tax laws and regulations; the Group’s ability to offer innovative, attractive products; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims, investigations and lawsuits; material operating expenditures in relation to compliance with health and safety regulations; the intense level of competition in the diagnostic/healthcare/life sciences industry, which may increase due to consolidation; the Group’s ability to fund its defined benefit pension plans; the ability to access funding to execute its business plans and improve its own businesses, financial condition and results of operations; the Group’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; commercial risk due to the fact that the Group operates in a market characterized by the presence of large competitors; risk associated to the maintenance of relationship with customers and strategic partners; risks associated with relationships with employees and suppliers; increases in costs, disruptions of supply or shortages of raw materials; developments in labor and industrial relations and developments in applicable labor laws; exchange rate fluctuations, interest rate changes, credit risk and other market risks; political and civil unrest; earthquakes or other disasters.

Any forward-looking statements contained in this document speak only as of the date of this document and DiaSorin disclaim any obligation to update or revise publicly forward-looking statements. Further information concerning the Group and its business, including factors that could materially affect the Group’s financial results, are included in DiaSorin’s reports and filings with CONSOB and Borsa Italiana.

No update. The information and opinions in this document is provided to you as of the dates indicated and DiaSorin does not undertake to update the information contained in this document and/or any opinions expressed relating thereto after its presentation, even in the event that the information becomes materially inaccurate, except as otherwise required by applicable laws.

Non-IFRS and Other Performance Measures. This document contains certain items as part of the financial disclosure, which are not defined under IFRS. Accordingly, these items do not have standardized meanings and may not be directly comparable to similarly-titled items adopted by other entities. DiaSorin management has identified a number of “Alternative Performance Indicators” (“APIs”). These APIs (i) are derived from historical results of DiaSorin and are not intended to be indicative of future performance, (ii) are non-IFRS financial measures and, although derived from the financial statements, are unaudited and (iii) are not an alternative to financial measures prepared in accordance with IFRS. The APIs presented herein include EBIT¹, EBITDA², adjusted EBITDA³, Net Financial Position⁴ and Free Cash Flow⁵. These measures are not indicative of historical operating results, nor are they meant to be predictive of future results. These measures are used by the management to monitor the underlying performance of the business and operations. Similarly entitled non-IFRS financial measures reported by other companies may not be calculated in an identical manner, consequently the measures reported in this document may not be consistent with similar measures used by other companies. Therefore, investors should not place undue reliance on this data.

¹ EBIT is defined as the “Operating Result” net of interests and taxes – ² EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group’s operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group’s operating result performance. - ³ Adjusted EBITDA is defined as Adjusted EBITDA, excluding extraordinary costs and expenses incurred in the Luminex transaction announced on April 11, 2021 - ⁴ The Net Financial Position is defined as the algebraic sum (positive balance sheet assets and negative balance sheet liabilities) of cash and cash equivalents and other current financial assets, minus current financial liabilities and non-current financial liabilities.-⁵ Free Cash Flow is defined as the set of means available to the Company and is equal to cash flows deriving from operating activities net of interest received or paid, and net of investments and divestments of fixed assets.

Financial Highlights*



Data in €/mln	Q2'22	Change		H1'22	Change	
		@ current	@ CER		@ current	@ CER
Revenues	328	+31.8%	+22.0%	685	+33.0%	+25.1%
Immunodiagnosics ex-COVID	173	+9.9%	+4.3%	333	+10.0%	+5.4%
Molecular Diagnostics ex-COVID	50	+212.9%	+178.7%	97	+170.9%	+147.8%
Licensed Technologies	52	n.m.	n.m.	106	n.m.	n.m.
COVID	53	-29.6%	-35.4%	150	-15.5%	-20.6%
Adjusted EBITDA	120	+4.5%	-2.7%	269	+10.2%	+4.1%
<i>Adjusted EBITDA Margin</i>	36.5%	-956 bps	-932 bps	39.3%	-813 bps	-796 bps
Adjusted EBIT	96	-4.2%		221	+3.1%	
<i>Adjusted EBIT Margin</i>	29.2%	-1,095 bps		32.3%	-937 bps	
Adjusted Net Result	72	-4.0%		169	+3.7%	
<i>% on revenues</i>	22.1%	-824 bps		24.6%	-693 bps	
Free Cash Flow				139		
Net Financial Debt				-1,003		

With reference to the Adjusted EBITDA, Adjusted EBIT and Adjusted Net Profit indicators, please refer to the table included in the financial schemes section of this presentation

H1 2022 key facts



Product Development

Molecular Diagnostics

- **New Simplexa™ SARS-CoV-2 Variants Direct Assay (Research Use Only)** for the detection and discrimination of mutations associated with circulating virus variants, including Omicron, without requiring upfront RNA extraction
- **xMAP® NxTAG® GPP Panel (CE Mark)** for the identification of the 16 most relevant pathogens associated with gastrointestinal infections in stool samples. The test is designed for use with the MAGPIX® platform and discriminates specific nucleic acids of bacteria, virus and parasites
- **ARIES® Flu A/B & RSV + SARS-CoV-2** for the differential diagnosis of the 4 most common respiratory viruses and their underlying respiratory infections

Immunodiagnosics

- **LIAISON® MeMed BV test 510(k) clearance** the first high throughput blood test to differentiate between bacterial and viral infections


Business Development

- **Appointment of Angelo Rago**, a senior executive with a 30+ years experience in MedTech global companies, as the new **President of Luminex**
- **Partnership with B-R-A-H-M-S GmbH**, part of Thermo Fisher Scientific, to develop and commercialize the new **LIAISON® B-R-A-H-M-S MR-proADM™**, a CLIA test which will aid in the diagnosis of a number of severe conditions (e.g. sepsis and septic shock, lower tract respiratory infections, urinary tract infections and kidney disease)
- **Execution of the project for the redefinition of the corporate structure of DiaSorin** to align it with the Group's organizational development and multinational profile, envisaged through the contribution in kind of the branch of business of DiaSorin related to the operating activities carried out in Italy and in the UK in favour of DiaSorin Italia S.p.A., a wholly owned direct subsidiary of the Company

Managerial outlook on Q2 and H1 2022 revenues


Total Q2 Group revenues (data in €/mln)

Data @CER Data @CUR



Total H1 Group revenues (data in €/mln)

Data @CER Data @CUR



■ Business ex-COVID ■ COVID-19 tests' sales

Evolution of the business in Q2'22

Positive results, driven by three separate trends:

- **BUSINESS EX-COVID:** +49.1% @CER vs. H1'21, mainly due to the inclusion of Luminex in the perimeter of consolidation and to the good performance of both the DiaSorin Immunodiagnostic and Molecular Diagnostic franchises
- **TOTAL COVID TESTS CONTRIBUTION** in H1'22 declined less than originally expected, closing at € 141 million at CER (-20.6%)
- **LUMINEX CONTRIBUTION:** € 185 million at current exchange rates and in line with budget expectations

Q2 and H1 2022 revenues growth by geography and technology



BY GEOGRAPHY	Q2'22 vs. Q2'21	H1'22 vs. H1'21
EUROPE DIRECT <ul style="list-style-type: none"> Positive performance of Immunodiagnosics ex-COVID sales (Latent TB, GI panel, ID panel) and significant contribution from COVID/Flu molecular tests' sales Positive impact on molecular diagnostic business from the inclusion of Luminex in the Group perimeter and DiaSorin COVID/Flu molecular tests' sales 	+16.4%	+16.8%
NORTH AMERICA DIRECT <ul style="list-style-type: none"> Positive trend of ex-COVID Immunodiagnostic sales due to the good performance of the U.S. hospital strategy and the latent tuberculosis test Positive impact from the inclusion of Luminex in the Group perimeter Good performance of the licensed technologies business, mainly due to the sales of xMAP® reagents and platforms 	+127.0%	+128.1%
REST OF THE WORLD <ul style="list-style-type: none"> Positive impact from inclusion of Luminex in the Group perimeter, partially offset by the negative trends of sales in China, mainly due to severe local lockdowns 	+7.1%	+11.2%
COVID <ul style="list-style-type: none"> Expected negative trend in COVID sales, despite inclusion of Luminex in the Group perimeter 	-35.4%	-20.6%


BY TECHNOLOGY		Q2'22 vs. Q2'21	H1'22 vs. H1'21
IMMUNODIAGNOSTICS EX-COVID	reported @ CER	+9.9% +4.3%	+10.0% +5.4%
MOLECULAR DIAGNOSTICS EX-COVID	reported @ CER	+212.9% +178.7%	+170.9% +147.8%
LICENSED TECHNOLOGIES		€ 52 mln	€ 106 mln
COVID	reported @ CER	-29.6% -35.4%	-15.5% -20.6%

H1 2022 revenues: managerial outlook


BY GEOGRAPHY

BY TECHNOLOGY


H1'21




H1'21



H1'22




H1'22



Q2 and H1 2022 profitability profile

(data in €/mln @ current exchange rates)



The Adjusted EBITDA mainly reflects the growth in revenues, while the decrease in profitability is largely due to the Luminex inclusion in the scope of consolidation and the resulting dilution of Gross Profit and reduction of operating leverage.

* With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation

FY 2022 Company Guidance



NEW FY 2022 GUIDANCE at 2021 CER:

- **REVENUES:** *around +2%* vs. FY'21, with COVID revenues at about € 200 million and ex-COVID revenues growing at *approx. 24%*
- **ADJUSTED EBITDA* MARGIN:** *approx. 38%*

* With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation



Financial schemes

Income Statement

(Amounts in million of euros)	Q2		H1	
	2021	2022	2021	2022
Net Revenues	248.7	327.8	515.4	685.4
Cost of sales	(78.5)	(113.1)	(160.1)	(235.9)
Gross profit	170.2	214.7	355.3	449.5
	68.4%	65.5%	68.9%	65.6%
Sales and marketing expenses	(37.9)	(73.4)	(74.7)	(141.9)
Research and development costs	(11.5)	(23.9)	(23.5)	(46.3)
General and administrative expenses	(18.9)	(29.0)	(37.9)	(56.8)
Total operating expenses	(68.3)	(126.2)	(136.1)	(244.9)
	27.5%	38.5%	26.4%	35.7%
Other operating income (expense)	(3.3)	(5.4)	(17.4)	(7.9)
<i>non recurring amount</i>	(1.2)	(2.9)	(12.9)	(4.2)
EBIT	98.5	83.0	201.9	196.7
	39.6%	25.3%	39.2%	28.7%
Net financial income (expense)	(5.0)	(7.5)	(5.7)	(14.9)
Profit before taxes	93.5	75.6	196.1	181.8
Income taxes	(21.7)	(17.1)	(46.1)	(41.0)
Net result	71.8	58.5	150.0	140.8
EBITDA²	113.4	117.0	231.3	263.6
	45.6%	35.7%	44.9%	38.5%

² EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

Adjusted Income Statement*

(Amounts in million of euros)	Q2		H1	
	2021	2022	2021	2022
Net Revenues	248.8	327.8	515.4	685.4
Cost of sales	(78.5)	(113.1)	(160.1)	(234.3)
Gross profit	170.2	214.8	355.3	451.2
	68.4%	65.5%	68.9%	65.8%
Sales and marketing expenses	(37.9)	(63.7)	(74.7)	(123.0)
Research and development costs	(11.5)	(23.7)	(23.5)	(46.0)
General and administrative expenses	(18.9)	(29.0)	(37.9)	(56.8)
Total operating expenses	(68.3)	(116.4)	(136.1)	(225.7)
	27.5%	35.5%	26.4%	32.9%
Other operating income (expense)	(2.1)	(2.8)	(4.5)	(4.1)
EBIT	99.8	95.6	214.7	221.4
	40.1%	29.2%	41.7%	32.3%
Net financial income (expense)	(1.6)	(2.2)	(2.3)	(3.7)
Profit before taxes	98.1	93.4	212.4	217.6
Income taxes	(22.8)	(21.1)	(49.9)	(49.1)
Net result	75.4	72.3	162.5	168.6
EBITDA²	114.6	119.7	244.2	269.1
	46.1%	36.5%	47.4%	39.3%

² EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

* With reference to the Adjusted measures please refer to the tables in the following slide

Reconciliation to consolidated financial statements

H1 2021

<i>Data in €/mln</i>	Gross Margin	EBITDA ²	EBIT	Fiscal Impact	Net Profit
IFRS Financial Statements Measures	355.3	231.3	201.9	n.a.	150.0
% on Revenues	68.9%	44.9%	39.2%		29.1%
Adjustments					
“One-off” Costs related to the acquisition of Luminex	-	12.9	12.9	(3.0)	9.9
Financial charges relating to debt instruments and to the convertible bond issued to finance the acquisition	-	-	-	(0.8)	2.6
Total Adjustments	-	12.9	12.9	(3.8)	12.5
Adjusted Measures	355.3	244.2	214.7	n.a.	162.5

H1 2022

<i>Data in €/mln</i>	Gross Margin	EBITDA ²	EBIT	Fiscal Impact	Net Profit
IFRS Financial Statements Measures	449.5	263.6	196.7	n.a.	140.8
% on Revenues	65.6%	38.5%	28.7%		20.5%
Adjustments					
Fair value measurement of the initial Luminex inventory	1.6	1.6	1.6	(0.4)	1.3
“One-off” Costs related to the acquisition, integration and restructuring of Luminex	-	3.9	3.9	(0.9)	3.0
Depreciation of Luminex intangibles identified in the Purchase Price Allocation	-	-	19.2	(4.3)	14.9
Financial charges relating to debt instruments and to the convertible bond issued to finance the acquisition	-	-	-	(2.5)	8.6
Total Adjustments	1.6	5.5	24.7	(8.1)	27.8
Adjusted Measures	451.2	269.1	221.4	n.a.	168.6

The alternative performance measures listed in the table should be used as an information supplement to the provisions of IFRS, to assist users of the document in better understanding the economic, equity and financial performance of the Group. Such measures are computed purifying the results of the one-off costs relating to the acquisition and integration of Luminex, of the amortization deriving from the Purchase Price Allocation and of the financial charges associated with the financing of the transaction, including the tax impact. It should also be noted that the method of calculating these adjusted indicators could differ from the methods used by other companies.

² EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

Balance Sheet

<i>(Amounts in million of euros)</i>	12/31/2021	06/30/2022	Change
Goodwill and intangibles assets	1,943.4	2,092.9	+149.5
Property, plant and equipment	276.2	289.9	+13.7
Other non-current assets	42.6	44.8	+2.2
Net working capital	361.9	407.8	+45.9
Other non-current liabilities	(270.2)	(286.7)	-16.5
Net Invested Capital	2,353.8	2,548.7	+194.8
Net Financial Debt	(985.9)	(1,003.1)	-17.2
Total shareholders' equity	1,367.9	1,545.5	+177.6

Cash flow statement

<i>(Amounts in million of euros)</i>	Q2		H1	
	2021	2022	2021	2022
Cash and cash equivalents at the beginning of the period	430.0	521.5	339.9	403.0
Cash provided by operating activities	71.9	45.7	173.7	180.1
Cash used in investing activities	(26.6)	(28.8)	(49.6)	(51.9)
Cash provided/(used) in financing activities	421.6	(155.9)	432.9	(148.8)
Net change in cash and cash equivalents before investments in financial assets	466.9	(139.0)	557.0	(20.6)
Net change in cash and cash equivalents	466.9	(139.0)	557.0	(20.6)
Cash and cash equivalents at the end of the period	896.8	382.4	896.8	382.4

DiaSorin

